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Hepatic cytochromes P450: structural degrons and barcodes, posttranslational
modifications and cellular adapters in the ERAD-endgame
Sung-Mi Kima, YongQiang Wanga, Noushin Nabavia*, Yi Liua and Maria Almira Correiaa,b,c,d
aDepartment of Cellular & Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA; bDepartment of
Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA; cDepartment of Bioengineering and
Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA; dThe Liver Center, University of California
San Francisco, San Francisco, CA, USA
ABSTRACT
The endoplasmic reticulum (ER)-anchored hepatic cytochromes P450 (P450s) are enzymes that
metabolize endo- and xenobiotics i.e. drugs, carcinogens, toxins, natural and chemical products.
These agents modulate liver P450 content through increased synthesis or reduction via inactiva-
tion and/or proteolytic degradation, resulting in clinically significant drug-drug interactions. P450
proteolytic degradation occurs via ER-associated degradation (ERAD) involving either of two dis-
tinct routes: Ubiquitin (Ub)-dependent 26S proteasomal degradation (ERAD/UPD) or autophagic
lysosomal degradation (ERAD/ALD). CYP3A4, the major human liver/intestinal P450, and the fast-
turnover CYP2E1 species are degraded via ERAD/UPD entailing multisite protein phosphorylation
and subsequent ubiquitination by gp78 and CHIP E3 Ub-ligases. We are gaining insight into the
nature of the structural determinants involved in CYP3A4 and CYP2E1 molecular recognition in
ERAD/UPD [i.e. K48-linked polyUb chains and linear and/or ‘‘conformational’’ phosphodegrons con-
sisting either of consecutive sequences on surface loops and/or disordered regions, or structurally-
assembled surface clusters of negatively charged acidic (Asp/Glu) and phosphorylated (Ser/Thr)
residues, within or vicinal to which, Lys-residues are targeted for ubiquitination]. Structural inspec-
tion of select human liver P450s reveals that such linear or conformational phosphodegrons may
indeed be a common P450-ERAD/UPD feature. By contrast, although many P450s such as the
slow-turnover CYP2E1 species and rat liver CYP2B1 and CYP2C11 are degraded via ERAD/ALD, lit-
tle is known about the mechanism of their ALD-targeting. On the basis of our current knowledge
of ALD-substrate targeting, we propose a tripartite conjunction of K63-linked Ub-chains, P450 struc-
tural ‘‘LIR’’ motifs and selective cellular ‘‘cargo receptors’’ as plausible P450-ALD determinants.
Abbreviations: AAA: ATPases associated with various cellular activities; ALD: autophagic lysosomal
degradation; BFA: bafilomycin A; CHIP: C-terminus of Hsc70-interacting protein; CuOOH: cumene
hydroperoxide; CPR: cytochrome P450 reductase; E1: Ub-activating enzyme; E2: Ub-conjugating
enzyme; E3: Ub-ligase complex; ER: endoplasmic reticulum; ERAD: ER-associated degradation;
gp78/AMFR: glycoprotein 78/autocrine motility factor receptor; HA: hemagglutinin; HMM: High
molecular mass; 3-MA: 3-methyladenine; MAP-LC3: microtubule-associated protein 1 light chain 3;
LIRs: LC3-interacting motifs; Lys-C: lysyl endopeptidase C; NBR1: neighbor of BRCA1 gene1; p62/
SQSTM1: sequestosome-1; PKA: protein kinase A; PKC: protein kinase C; RING: Really interesting
new gene; Rpn: (non-ATPase) lid 26S subunits; Rpt: AAA ATPase base 26S subunits; ROS: reactive
O2 species; TAO: troleandomycin; Ub: ubiquitin; UPD: Ub-dependent 26S proteasomal degradation;
VCP: Valosin-containing protein; VIM: VCP-interacting motif
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Introduction
Cellular pathways for hepatic P450 degradation
Budding yeast and higher eukaryotic cells possess many
different proteolytic processes for the basal turnover/
disposal of senescent and/or structurally damaged
organelles, and misfolded, aggregated and/or function-
ally inactivated proteins, thereby providing not only
quality control but also enabling the salvage of their
constituent building blocks (i.e. amino acids from pro-
teins, fatty acids from lipoproteins, sugars from glyco-
proteins) for recycling and/or reutilization as energy
sources. Of these, a relatively well-characterized process
to date is the endoplasmic reticulum (ER)-associated
degradation (ERAD), an ER-quality control system
(Christianson & Ye, 2014; Hampton & Garza, 2009; Hirsch
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et al., 2009; Nakatsukasa et al., 2008; Olzmann et al.,
2013; Vembar & Brodsky, 2008), with three distinct
mechanistic pathways in the yeast S. cerevisiae (Ahner &
Brodsky, 2004; Carvalho et al., 2006; Taxis et al., 2003;
Vashist & Ng, 2004): ERAD-L for the disposal of mis-
folded/damaged ER-lumenal (L) proteins, ERAD-M for
the misfolded/damaged polytopic ER-membrane (M)-
anchored proteins such as HMG CoA reductase, and
ERAD-C for that of monotopic ER-membrane anchored
proteins with misfolded/damaged cytosolic (C) domains
such as in principle, the hepatic cytochromes P450
(P450s). Each of these ERAD pathways, particularly in S.
cerevisiae, is known to entail specific accessory adapters
and/or participating ubiquitination modules that pre-
dominantly target the ER-proteins to ubiquitin (Ub)-
dependent 26S proteasomal degradation (UPD)
(Christianson & Ye, 2014; Olzmann et al., 2013).
However, in mammalian cells, the subsequent recogni-
tion that while a given ER-protein in its native state
incurred ERAD-L, ERAD-M or ERAD-C depending on its
ER-topology, but opted for the autophagic-lysosomal
degradation (ALD) when aggregated, gave rise to the
ERAD-I and ERAD-II nomenclature for the former 3 ERAD
pathways requiring UPD, and the latter pathway requir-
ing ALD instead of UPD, respectively (Fujita et al., 2007).
Nine P450s (CYPs 3A4, 2C9, 1A2, 2E1, 2D6, 2C8, 2C19,
2A6 and 2B6, listed in decreasing order of their relative
hepatic abundance) are primarily responsible for the
oxidative metabolism of drug/xenobiotic substrates in
the human liver (Guengerich, 2015). These hepatic
P450s, along with their rabbit, rat and mouse orthologs,
qualify as excellent prototypes of ERAD-C substrates by
virtue both of their monotopic Type I ER-topology (i.e. a
bulky cytosolic catalytic domain anchored to the
ER-membrane via a single N-terminal 30–33-residue
long amphipathic helix) and their cytosolic domain
prone to oxidative/structural lesions stemming from
their oxidative function that engenders highly reactive
O2 species (ROS) (Ekstrom & Ingelman-Sundberg, 1989;
Goasduff & Cederbaum, 1999; Gorsky et al., 1984;
Zhukov & Ingelman-Sundberg, 1999). However, in spite
of these common features, not all P450 proteins pre-
dominantly subscribe to the canonical ERAD-C/ERAD-I
process, henceforth referred to as ERAD/UPD pathway.
Thus, although all CYPs 3A as well as all structurally/
functionally inactivated P450s are predominantly ERAD/
UPD targets (Correia et al., 1987, 1992a, 1992b, 2005;
Correia, 2003; Correia & Liao, 2007; Dai & Cederbaum,
1995; Faouzi et al., 2007; Korsmeyer et al., 1999; Liao
et al., 2006; Lee et al., 2008; Murray & Correia, 2001;
Morishima et al., 2005; Roberts, 1997; Schmiedlin-Ren,
1997; Sohn et al., 1991; Tierney et al., 1992; Wang et al.,
1999), native P450s such as rat liver CYPs 2B1 and 2C11
are predominantly ERAD-II substrates requiring ALD
instead of UPD, henceforth referred to as the ERAD/ALD
pathway (Liao et al., 2005; Masaki et al., 1987; Murray
et al., 2002; Ronis & Ingelman-Sundberg, 1989; Ronis
et al., 1991). On the other hand, human or rat liver
CYP2E1 utilizes both ERAD/UPD and ERAD/ALD path-
ways, depending on whether it is suicidally inactivated
or native/substrate-free, or native/substrate-bound,
respectively (Bardag-Gorce et al., 2002; Morishima et al.,
2005; Roberts et al., 1995; Song et al., 1989; Wang et al.,
2011). Thus, although a preferential P450 routing into
either pathway apparently exists, the pathway not
chosen may simply represent a convenient alternative
backup, in eventualities such as ER-stress when ERAD/
UPD is overloaded and clogged with misfolded/aggre-
gated proteins awaiting clearance, and competition for
the ERAD/UPD cellular machinery is insurmountable. It is
worth noting however, that P450 ERAD in cultured hep-
atocytes may not always faithfully reflect the preferen-
tial physiological sorting of any given P450 in vivo, as
cultured cells are usually subjected to much higher
O2-concentrations than normally encountered in the
liver of the intact animal, and thus more vulnerable to
oxidative insults.
P450 ERAD/UPD
The elucidation of hepatic CYP3A and CYP2E1 ERAD has
provided the essential blueprint for this P450 degrad-
ation pathway. Such ERAD involves posttranslational
phosphorylation of the P450 proteins by cytosolic kin-
ases (Korsmeyer et al., 1999; Wang et al., 2001; Wang
et al., 2009, 2011, 2012, 2015), their ubiquitination by
the concerted action of the E1-Ub-activating enzyme, E2
Ub-conjugating enzyme/E3 Ub-ligase complexes (Kim
et al., 2010; Morishima et al., 2005; Pabarcus et al., 2009;
Wang et al., 2009, 2011, 2012, 2015), and subsequent
degradation by the cytosolic 26S proteasome (Correia
et al. 1992b, 2005; Correia, 2003; Correia et al., 2005;
Correia & Liao, 2007; Faouzi et al., 2007; Liao et al., 2006;
Murray & Correia, 2001; Morishima et al., 2005; Roberts,
1997; Tierney et al., 1992; Figure 1). The 26S proteasome
consists of a 20S proteolytic barrel topped at each end
by a 19S regulatory cap, with Ub-chain recognition/deu-
biquitinating Rpn (non-ATPase) lid subunits (specifically
Rpn10 and Rpn13 Ub-chain receptors/Rpn11 deubiquiti-
nase) as well as Rpt AAA (ATPases associated with vari-
ous cellular activities) ATPase base subunits for protein
unfolding. As the Rpt ATPases grasp and unfold
the ubiquitinated proteins, the Rpn10 and Rpn13 Ub-
receptors situated immediately above the base engage
the Ub-chains, enabling Rpn13 to deubiquitinate and
recycle the Ub-chains for fresh ubiquitination cycles.
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The bare, unfolded protein target is then threaded into
the narrow 20S central proteolytic cavity with a pore
diameter of merely 13–14 Å (Finley, 2009; Pickart &
Cohen, 2004; Rechsteiner, 2005).
In common with the ERAD of polytopic ER-integral
and ER-luminal proteins, ERAD/UPD of these P450 pro-
teins also requires their extraction out of the ER into the
cytosol by the p97/VCP (Valosin-containing protein)
AAA-ATPase, an abundant cytosolic chaperone (Bar-Nun,
2005; Chou et al., 2011; Dai & Li, 2001; Elkabetz et al.,
2004; Ikeda et al., 2009; Jentsch & Rumpf, 2007; Meyer
et al., 2000; Richly et al., 2005; Xia et al., 2016; Ye et al.,
2005), and/or the 19S proteasomal cap Rpt4 AAA-
ATPase subunit (Lipson et al., 2008), before subsequent
proteasomal degradation.
Several inhibitors [i.e. vinyl sulfone, MG-132, MG-262,
lactacystin, epoxomycin, PS-341 (Bortezomib/Velcade; a
boronated MG-132)] that specifically target the 20S pro-
teasomal chymotrypsin-like (b5)-, caspase-like (b1)-,
and/or trypsin-like (b2)-subunit N-terminal Thr-proteases
either reversibly or irreversibly are commercially avail-
able, for use as diagnostic probes of this ERAD/UPD-
pathway (Dick et al., 1997; Lee & Goldberg, 1998;
Rechsteiner, 2005; Rock et al., 1994). However, not all of
these agents inhibit these three 20S proteasomal pro-
teolytic activities equivalently. Some are more selective
and/or potent inhibitors of just one rather than all three
protease activities. Additionally, it is important to recog-
nize that these inhibitors block UPD at a step beyond
P450 protein ubiquitination. Thus, an accurate
assessment of their effectiveness as ERAD/UPD blockers
with consequent stabilization of the relevant P450s
requires monitoring the stabilization of both the parent
( 50 kDa) and the ubiquitinated P450 species [>65 kDa
high molecular mass (HMM)].
Cellular protein kinases and protein
phosphorylation in P450 ERAD
The 1962 seminal finding that catecholamine adminis-
tration could depress hepatic drug metabolism in rats
(Fouts, 1962) implicated cAMP-signaling, thus instigating
the subsequent documentation that the cyclic AMP ana-
log N6, O2-dibutyryl cAMP could similarly lower hepatic
microsomal P450 content in vivo, due to P450 protein
phosphorylation that denatured the hemoprotein to its
inactive, spectrally detectable P420 species (Hutterer
et al., 1975). This finding spurred a flurry of subsequent
investigations by various research groups over several
decades on the precise site, role and/or purpose of such
P450 phosphorylation (literature extensively reviewed by
Aguiar et al., 2005; Correia, 2003; Correia et al., 2014;
Correia & Liao, 2007; Korsmeyer et al., 1999).
More germane to the present P450 ERAD discussion,
however, are the findings of Ingelman-Sundberg and
colleagues (Eliasson et al., 1990, 1992, 1994; Johansson
et al., 1991) who showed both in cultured hepatocytes
and in in vitro reconstituted systems that such micro-
somal CYP2E1 and CYP3A1 phosphorylation actually
predisposes these P450s, but not CYP2B1, to an
Figure 1. CYP3A4 ERAD/UPD: Known cellular participants. See discussion for details.
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ERAD-like process, that although independent of either
ubiquitination and/or the 26S proteasome (and thus de
facto UPD-independent), required intrinsic ER-kinases
and ER-integral Mg2þ-ATP-activated proteolytic systems.
Accordingly, these investigators showed that glucagon
or 8-bromo-cAMP-treatment of cultured rat hepatocytes
resulted in the phosphorylation and rapid degradation
of these P450s that was blocked by their select sub-
strates/inhibitors (Eliasson et al., 1992, 1994). Using
microsomal P450s in vitro, they further documented the
involvement of an endogenous microsomal serine kin-
ase, proceeding independently of any external kinase,
but which in purified systems could be replaced by the
catalytic subunit of a bovine cAMP-dependent protein
kinase (PKA) (Eliasson et al., 1992, 1994). Such P450 pro-
tein phosphorylation was enhanced by incubation with
NADPH and was associated with a spectroscopically
detectable denaturation to P420 and consequent func-
tional inactivation, which was blocked by select CYP2E1
and CYP3A substrates/inhibitors such as EtOH, imidazole
or acetone and clotrimazole, troleandomycin (TAO) or
erythromycin, respectively (Eliasson et al., 1992, 1994).
Through HPLC-analyses of peptide digests, the authors
further identified the P450 phosphorylation sites as
CYP2E1 Ser129 (Eliasson et al., 1990, 1992), a finding
consistent with the dibasic PKA-consensus motif (RR-X-
S), and CYP3A4 Ser-393, a less common PKA-consensus
site (Eliasson et al., 1994). This group proceeded to pur-
ify two forms of membrane bound serine proteinases
(MW 32 000 kDa; pH 8.0 optimum) from rat liver micro-
somes that were documented to degrade not only
CYP2E1 over a 19 h-period with a profile similar to that
of liver microsomal CYP2E1 (Zhukov et al., 1993), but
also CYP3A1 and CYP2B1 (Eliasson et al., 1994).
Equally pertinent to this discussion are the findings
(Lohr & Kuhn-Welten, 1997) that an ER-bound PKA was
responsible for the phosphorylation of testicular micro-
somal CYP17 and its subsequent targeting to an uniden-
tified cytosolic ATP-dependent protease, most likely, the
26S proteasome. Our own studies, however, of cumene
hydroperoxide (CuOOH)-inactivated CYP2B1 (Korsmeyer
et al., 1999) and CYP3A4 (Wang et al., 2001) identified
not only microsomal and cytosolic kinases such as PKA
and PKC, but also invariably an UPD process. In retro-
spect, these findings foretold a role for both ER/cytosolic
kinases as well as E2/E3-complexes and the 26S prote-
asome, as in our current understanding of P450
ERAD/UPD.
More recent LC-MS/MS analyses of human liver sam-
ples by Redlich et al. (2008) confirmed that Ser129 is
indeed a CYP2E1 phosphorylation site. Our own LC-MS/
MS analyses of in vitro phosphorylated human liver
CYP2E1 peptide digests further revealed that Ser129 is a
major (>98%) PKA-phosphorylation site both in the
native and CuOOH-inactivated proteins (Wang et al.,
2011). This residue is also correspondingly phosphory-
lated by PKC to>23% and 32%, respectively (Wang
et al., 2011). However, the advent of much more sensi-
tive LC-MS/MS methodology has led to the recognition
that Ser129 is but one of 16 different CYP2E1 S/T-resi-
dues that are phosphorylated. Because CYP2E1 Ser129
mutation to Ala or Gly had little effect on its turnover
upon transfection into COS 7 cells (Freeman & Wolf,
1994), we believe that some of these other 16 phos-
phorylated residues must be involved, as phosphoryl-
ation does indeed significantly enhance both CYP2E1
and CYP3A4 ERAD/UPD (Correia et al., 2014; Wang et al.,
2009, 2011, 2012, 2015). Indeed, similar analyses of
in vitro phosphorylated CYP3A4 revealed that PKA phos-
phorylates 5 Ser residues (S116, S119, S134, S259 and
S478), whereas PKC phosphorylates 14 Ser/Thr residues
(T92, S100, T103, S116, S119, S131, S134, T136, S139,
S259, T264, T284, S398, S420). It is noteworthy that S393
identified earlier as a PKA-phosphorylation site (Eliasson
et al., 1994) is absent in CYP3A4, but its vicinal S398
(present in most CYPs 3A) is detectably phosphorylated
by PKC, but not PKA (Wang et al., 2012).
Of these 15 recently identified CYP3A4 phosphoryl-
ation sites, S134 was previously identified in human liver
samples (Redlich et al., 2008), whereas we had identified
T264 and S420 as PKC phosphorylated residues (Wang
et al., 2001; Wang et al., 2009) and S478 as PKA-phos-
phorylation site (Wang et al., 2009). When the relevance
of the phosphorylatable residues T264, S420 and S478
to CYP3A4 ubiquitination was probed through site-
directed mutagenesis, their mutation to Ala was found
to considerably reduce its extent (Wang et al., 2012).
Furthermore, of these three, the PKA-phosphorylatable
S478-residue had by far the most pronounced impact,
even though it is phosphorylated just by PKA to a very
low extent ( 0.32% and 1.29% in the native and
CuOOH-inactivated proteins, respectively; Wang et al.,
2012). Thus, it appears that the precise site rather than
the extent of S/T-phosphorylation is a critical determin-
ant. Interestingly, CYP3A5 that has a phosphomimetic
D478 instead of S478 is constitutively ubiquitinated to a
much greater extent than CYP3A4, but not degraded
quite as rapidly (Wang et al., 2012). Although, the rele-
vance of the other 12 phosphorylated CYP3A residues
has not been quite as extensively probed, yet we now
know that S259 and T284, as constituents of two
CYP3A4 phosphodegrons (see below) are also quite rele-
vant to its ubiquitination by E2/E3-complexes (Wang
et al., 2015). Collectively, these findings argue that phos-
phorylation is an important determinant of P450 ERAD/
UPD, albeit not the only one.
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E2/E3 Ub-ligase complexes participating in P450
ERAD/UPD
Just two well-defined E2/E3-complexes operate in bud-
ding yeast i.e. Ubc6p/Ubc7p/Cue1p/Hrd1p complex
engaged in ubiquitinating substrates in the ERAD-M and
ERAD-L pathways, whereas the Ubc6p/Ubc7p/Doa10p
complex is responsible for ubiquitinating ERAD-C sub-
strates as well as cytosolic proteins (Christianson & Ye,
2014; Hirsch et al., 2009; Kostova et al., 2007; Metzger
et al., 2012; Ravid et al., 2006). By contrast, mammalian
cells posess a greatly expanded repertoire of E2/E3-
complexes devoted to ERAD, including the Hrd1p-ortho-
logs Hrd1 and gp78/AMFR (autocrine motility factor
receptor), the Doa10p-ortholog TEB4/MARCH VI, RNF5/
RMA1, RNF170 and CHIP (C-terminus of Hsc70-interact-
ing protein) (Ballinger et al., 1999; Chen et al., 2006,
2012; Edkins, 2013; Fang et al., 2001; Hirsch et al., 2009;
Jiang et al., 2001; Kikkert et al., 2004; Kostova et al.,
2007; McDonough & Patterson, 2003; Metzger et al.,
2012; Murata et al., 2001; Olzmann et al., 2013; Peng
et al., 2004; Rosser et al., 2007). With the exception of
CHIP that is cytosolic, these other E3s are all integral
membrane proteins. Initial studies in S. cerevisiae strains
with genetic Hrd1p- and Doa10p-deletions excluded
these particular E3s in CYP3A4 ERAD/UPD (Liao et al.,
2006; Murray & Correia, 2001), a finding that was vali-
dated when the corresponding purified, recombinant
mammalian orthologs (Hrd1 and TEB4) were tested in in
vitro functionally reconstituted CYP3A4-E2/E3-ubiquiti-
nation systems (Pabarcus et al., 2009). These studies of
CYP3A4-ubiquitination also included in parallel, two
other plausible E3 Ub-ligases: gp78 and CHIP, which
were both capable of ubiquitinating CuOOH-inactivated
CYP3A4 (Pabarcus et al., 2009).
gp78/AMFR
This polytopic E3 is found integrated via its N-terminal
308 residues both in the ER- and plasma membranes,
with its functional domain in the cytosol wherein it inter-
acts with its cognate E2 Ubc7/Ube2g2 and the rest of
the requisite ubiquitination machinery to target cytosolic
domains of integral ER-proteins (i.e. P450s) (Chen et al.,
2006, 2012; Das et al., 2009, 2013; Fang et al., 2001;
Hirsch et al., 2009; Kostova et al., 2007; Kim et al., 2010;
Metzger et al., 2012; Olzmann et al., 2013; Pabarcus
et al., 2009) as well as cytosolic proteins [i.e. tryptophan
2,3-dioxygenase (TDO)] (Kim et al., 2016a). gp78 is critic-
ally involved in substrate recognition and subsequent
catalytic transfer of the Ubc7-elaborated polyUb chain
en bloc onto the substrate (Chen et al., 2006, 2012; Fang
et al., 2001; Hirsch et al., 2009; Kim et al., 2010; Kostova
et al., 2007; Li et al., 2007, 2009; Metzger et al., 2012;
Olzmann et al., 2013; Pabarcus et al., 2009). Its cytosolic,
functionally active C-terminal domain (309–643 residues)
is composed of an intrinsic RING-finger Ub-ligase (resi-
dues 341–378), Cue1-like domain (residues 456–497) for
binding Ub and elongating polyUb-chains, Ubc7/
Ube2g2-binding (G2BR; residues 579–600), substrate rec-
ognition and putative p97/VCP-interacting motif (VIM;
residues 626–643) (Chen et al., 2006, 2012; Das et al.,
2009, 2013; Fang et al., 2001; Kostova et al., 2007;
Metzger et al., 2012). Except for VIM, all the other gp78-
domains are essential for Ubc7-dependent CYP3A4-ubiq-
uitination (Wang et al., 2015). Lentiviral shRNAi-mediated
gp78-knockdown in cultured rat hepatocytes verified its
physiological role in CYP3A ERAD (Kim et al., 2010). Such
gp78-knockdown not only significantly stabilized both
ER-integral parent and ubiquitinated CYP3A species, but
also enhanced their functional content (Kim et al., 2010).
This indicated that although other CYP3A-ERAD-associ-
ated E3s were present, they could not compensate for
the cellular knockdown of gp78.
Chemical crosslinking coupled with LC-MS/MS analy-
ses of Ubc7/gp78-ubiquitinated CYP3A4 peptide digests
revealed that CYP3A4-K251, flanking its negatively
charged (E258-pS259-E262-D263-pT264) DEST-cluster,
interacts with gp78-K313 residing in a positively
charged (R307-R308-R310-H312-K313) patch flanking
the Ubc7-interacting gp78-RING finger domain, whereas
CYP3A4-K257 is found crosslinked to gp78-K586 in
another positively charged Q584-R585-K586 patch
within the gp78-C-terminal Ubc7-interacting-G2BR
domain (Wang et al., 2015). Simultaneous site-directed
mutagenesis of both these positively charged gp78
patches were found to attenuate not only its CYP3A4
ubiquitination in vitro (Wang et al., 2015), but also that
of human CYP2E1 (Figure 2), another P450 ubiquitinated
by the Ubc7-gp78 complex (Wang et al., 2011). Notably,
CYP3A4-K251, K257 and K266 along with several other
CYP3A4-residues (K127, K141, K168, K209, K413, K421,
K424 and K487) were also found cross-linked to its cog-
nate E2 (Ubc7), consistent with both the critical ultimate
Ub-donor role of Ubc7, and the dynamic nature of the
inherent CYP3A4-Ubc7/gp78 electrostatic interactions
within this ubiquitination system (Wang et al., 2015).
CHIP
This cytosolic U-box E3 Ub-ligase engages UbcH5a as its
cognate E2-partner and functions cooperatively as a co-
chaperone of Hsp70/Hsp40 in UPD substrate-recruit-
ment (Ballinger et al., 1999; Clapp et al., 2012; Edkins,
2013; Jiang et al., 2001; McDonough & Patterson, 2003;
Morishima et al., 2005; Murata et al., 2001; Peng et al.,
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2004; Rosser et al., 2007). It is a 303-residue long,
38.4 kDa protein containing three tandem tetratricopep-
tide repeats (TPR) in its N-terminal domain for Hsc/
Hsp70- and Hsp90-binding, and a C-terminal RING-finger
like U-box that is evolutionarily very highly conserved.
Because yeasts lack CHIP (Vembar & Brodsky, 2008), its
role in CYP3A4 ERAD could not be predicted a priori
from our studies in S. cerevisiae (Liao et al., 2006; Murray
& Correia, 2001). However, CHIP was documented to
ubiquitinate various proteins including CFTR, its co-
chaperone Hsp70, the androgen, estrogen and gluco-
corticoid receptors (Ballinger et al., 1999; Edkins, 2013;
Jiang et al., 2001; McDonough & Patterson, 2003; Rosser
et al., 2007; Younger et al., 2006), and most tellingly, the
P450-like hemoprotein neuronal nitric-oxide synthase
(Clapp et al., 2012; Peng et al., 2004), as well as the
recombinant rabbit CYP2E1 and CYP2B4 in vitro
(Morishima et al., 2005). This collective evidence coupled
with our preliminary finding that CYP3A4 was indeed
stabilized in a temperature sensitive Hsp70-defective
yeast mutant (ssa1–45; Vembar & Brodsky, 2008),
prompted the examination of its ability to ubiquitinate
human CYP3A4 (Kim et al., 2010; Pabarcus et al., 2009;
Wang et al., 2009, 2012, 2015) and CYP2E1 (Morishima
et al., 2005; Wang et al., 2011) in in vitro functionally
reconstituted ubiquitination systems. Such in vitro
CYP3A4 and CYP2E1-ubiquitination suggested its
involvement in P450 ERAD in vivo (Figure 1).
Accordingly, shRNAi-elicited hepatic CHIP knockdown in
cultured rat hepatocytes of 80% led to a corre-
sponding 2.5-fold stabilization of functionally active
CYP3A (Kim et al., 2010) and CYP2E1 ER-content (Kim
et al., 2016b), thereby verifying the physiological role of
CHIP in P450 ERAD. Once again its function, as that of
gp78, was also neither redundant nor compensated by
any of the numerous cellular E3s (including hepatic
gp78), functional in ERAD.
Chemical crosslinking coupled with LC-MS/MS analy-
ses of CYP3A4 ubiquitinated by the fully reconstituted
Hsp70/Hsp40/UbcH5a/CHIP-system revealed just two
direct links of CYP3A4-K257 with CHIP-K125, and
CYP3A4-K421 with CHIP-K22, whereas 9 different cross-
links were found between CYP3A4 residues (K127, K141,
K168, K257, K266, K421) and one of 4 UbcH5a-residues
(K4, K8, K133, K144) (Wang et al., 2015). Just one cross-
link between CYP3A4-K266 and Hsp70-K512 was
detected (Wang et al., 2015), not all surprisingly given
that Hsp70 is known to interact with its targets largely
via hydrophobic domains. Interestingly, CYP3A4-K257
and K266 residues flank the same surface acidic (E258-
pS259-E262-D263-pT264) DEST-cluster that is relevant
for its Ubc7-gp78 interactions.
Intriguingly, the CHIP complex is able to elaborate
K11-, K48- and K63-Ub-linkages in in vitro functionally
reconstituted P450-ubiquitination systems (Wang et al.,
2012). This suggests that it may also be capable of
diverting K48-Ub-linked ubiquitinated P450 proteins to
ERAD/UPD, and K63-linked ubiquitinated P450 proteins
to ERAD/ALD (see discussion below). Indeed on the basis
of studies with structural deletion CHIP-mutants, a role
for CHIP as a molecular switch between these two cellu-
lar degradation pathways has been proposed in its tar-
geting of a-synuclein to its UPD via its Hsp70-interacting
TPR domain, and to ALD via its catalytic U-box
(Shin et al., 2005).
Complementary rather than redundant roles of
gp78 and CHIP E3 ligases in P450 ERAD
Several examples now exist in the literature indicating
that in mammalian cells, more than one E2/E3 Ub-ligase
complex can concomitantly target the same proteins as
substrates (Imai et al., 2002; Jo et al., 2011; Lu et al.,
2011; Morito et al., 2008; Shmueli et al., 2009; Wang
et al., 2014, 2015; Ying et al., 2011; Younger et al., 2006;
Zhang et al., 2015), thus revealing that they are not
quite redundant and/or need not compete for the sub-
strate target in question, but rather act synergistically
and/or cooperatively. In doing so, it is unclear whether
they select a given substrate molecule in parallel, simul-
taneously targeting different and/or multiple K-residues
Figure 2. gp78-mediated ubiquitination of CYP2E1:
Involvement of the same gp78 basic patches involved in its
intermolecular electronic interactions with CYP3A4. This was
documented in in vitro functionally reconstituted E1/E2/E3 sys-
tems in the presence or absence of either CYP2E1 or CYP3A4
or ATP, using either recombinant gp78 wild type (WT) or its
patch mutant (PT) wherein its positively charged residues
R307-R308-R310-H312-K313/Q584-R585-K586 (known to interact
with certain CYP3A4 DEST clusters) were mutated to Ala via
site-directed mutagenesis (Wang et al., 2015). Color code
wheel: Red> orange> yellow> green> blue> indigo> violet.
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in discrete surface domains, or whether they act in tan-
dem according to some preordained ‘‘hierarchical organ-
ization of prioritized substrate-E3 relationships’’
(Christianson & Ye, 2014). Several lines of evidence
strongly suggest that a similar hierarchical targeting
may indeed occur in P450 ERAD: First, upon shRNAi-eli-
cited gp78-knockdown, although CYP3A ER-export into
the cytosol and thus its UPD were considerably reduced
in cultured rat hepatocytes, significant CYP3A ubiquiti-
nation (detected as HMM 35S-species) was found to still
persist both in the ER and cytosol (Kim et al., 2010).
Thus gp78 knockdown had reduced, but did not
altogether abolish CYP3A ubiquitination and conse-
quent ER to cytosol export (Kim et al., 2010). By contrast,
similar shRNA-mediated CHIP knockdown completely
abrogated both CYP3A ubiquitination and its ER to cyto-
sol export, even though gp78 was functionally
unaffected (Kim et al., 2010). These findings revealed
that ‘‘in vivo’’ CHIP may function quite early as an E3 to
prime CYP3A ubiquitination in the ER, and that after
such initial CHIP-mediated CYP3A priming, gp78 may
serve as an E4 to extend the already initiated Ub-chains
(Chen et al., 2012; Kostova et al., 2007; Morito et al.,
2008; Wang et al., 2014). Second, the findings that
although each functionally reconstituted E2/E3-system
could individually support CYP3A4-ubiquitination, but
simultaneous inclusion of both these E2/E3 systems
robustly potentiated their CYP3A4-ubiquitination with
even greater elongation of HMM CYP3A4 Ub-conju-
gates, underscores their synergistic interactions (Wang
et al., 2015). Furthermore, the exclusion of just CHIP in
the first 30min of this dual E2/E3-incubation attenuated
the overall CYP3A4-ubiquitination and its extension to
higher HMM-ubiquitinated species to a much greater
extent than the omission of just gp78 during this initial
30min-period. This similarly points to sequential interac-
tions in a predetermined hierarchical order wherein
CHIP serves as the E3 to prime P450 for ubiquitination,
with gp78 then acting as an E4 to elongate these Ub-
chains (Wang et al., 2015). Additionally, although each
of these two E3-ligases can individually target specific
K-residues in topologically different CYP3A4 surface
clusters, their target sites (i.e. CYP3A4 K127, K168, K492)
are not mutually exclusive (Wang et al., 2012). Further
support for such complementary rather than redundant
roles of these E2/E3 systems is also derived from their
intermolecular interactions with some of the same
CYP3A4 K-residues (K257, K266) flanking or within the
acidic (E258-pS259-E262-D263-pT264) surface cluster
(Wang et al., 2015). Thus, Ala-mutation of the residues
within this cluster greatly attenuated CYP3A4 ubiquitina-
tion by the dual E2/E3-system. These findings suggest
that although gp78 can per se effectively ubiquitinate
P450s (and its other substrates) in in vitro reconstituted
systems, it can function both as an E3 and an E4 in
ERAD/UPD (Kim et al., 2010; Pabarcus et al., 2009; Wang
et al., 2009, 2011, 2012, 2015). A similar E4-role has been
ascribed to CHIP in its promotion of Parkin-mediated
ubiquitination of the unfolded Pael receptor (Imai et al.,
2002).
P450 ERAD/ALD
Unlike P450 ERAD/UPD, relatively little is known about
the sorting mechanisms and cellular participants
involved in P450 ERAD/ALD. ALD is a highly conserved
eukaryotic process, once thought to involve the bulk
degradation of senescent, long-lived proteins/organelles
as well as cytosolic components following starvation
(Cuervo, 2011; Klionsky et al., 2010; Mizushima et al.,
2008; Rabinowitz & White, 2010; Rubinsztein et al.,
2012). It is now recognized to be both a rather tightly
regulated and selective process entailing macroautoph-
agy with subsequent lysosomal degradation (Bento
et al., 2016; Cuervo, 2011; Klionsky et al., 2010;
Mizushima et al., 2008, 2010; Madrigal-Matute & Cuervo,
2015; Ohsumi, 2014; Rabinowitz & White, 2010;
Rubinsztein et al., 2012; Wen & Klionsky, 2016; Yang &
Klionsky, 2009). Macroautophagy (or autophagy for
short) involves the concerted function of over 35
autophagy-related genes (ATGs; Bento et al., 2016;
Cuervo, 2011; Klionsky et al., 2010; Madrigal-Matute &
Cuervo, 2015; Mizushima et al., 2008; Mizushima et al.,
2010; Ohsumi, 2014; Rabinowitz & White, 2010;
Rubinsztein et al., 2012; Wen & Klionsky, 2016; Yang &
Klionsky, 2009) that generate multiprotein complexes
that act cooperatively and sequentially to deliver the
cargo for lysosomal degradation (Figure 3). This process,
distinct from microautophagy (Madrigal-Matute &
Cuervo, 2015) or chaperone-mediated autophagy
(Madrigal-Matute & Cuervo, 2015), is initiated by the for-
mation of an isolation membrane or ‘‘phagophore’’ of
somewhat still uncertain and thus debatable cellular ori-
gin. This step requires both the Unc-51-like kinase
(ULK1) complex that phosphorylates a Beclin I-com-
plexed class III phosphoinositol-3 kinase [PI3K], a target
of 3-methyladenine (3-MA), LY294002 or wortmannin
(Mizushima et al., 2010). Upon choosing its cargo (i.e. a
P450), the isolation membrane elongates and then fuses
to form a double-membrane vesicle known as the
‘‘autophagosome’’. This step is critically dependent on
the Atg5-Atg12-Atg16-WD-repeat (WIPI) protein-
dependent conversion of microtubule-associated pro-
tein 1 light chain 3 (MAP-LC3, or LC3 for short, a
mammalian homolog of yeast Atg8) from LC3-I (free
form) to LC3-II (membrane-bound form) upon
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conjugation with phosphatidylethanolamine (PE), a lipid
enriched in the isolation membrane. Indeed, LC3-I to
LC3-II conversion is a critical hallmark used as a bio-
chemical and/or morphologic marker of cellular auto-
phagic induction (Mizushima et al., 2010). Cargo
selection and subsequent sequestration is dependent
on LC3-interacting motifs ‘‘LIRs’’ of target substrates
and/or accessory adapters such as p62 and/or NBR-1,
the cargo receptors for ubiquitinated substrates and/or
protein aggregates (Birgisdottir et al., 2013; Johansen &
Lamark, 2011; Lamark et al., 2009; Stolz et al., 2014).
Fusion of the cargo-sequestering autophagosome with
a lysosome generates the autolysosome, wherein lyso-
somal proteases degrade the cargo, and the end prod-
ucts are either recycled or consumed as an energy
source. Although only the defined milestones common
to this ALD process are underscored here (Figure 3), it is
highly likely that P450s like other ALD substrates (Bento
et al., 2016; Klionsky et al., 2010; Rubinsztein et al.,
2012), incur a well-orchestrated, multi-step journey
along cytoskeletal elements (microtubules and kinesin/
dynein motors) from the ER to the lysosome, paved by
various different ATG-protein complexes, kinases, cargo
receptors, and/or membrane-tethering factors.
Additionally, an alternate subfamily of ATG8-homologs
GABARAPs/GATE-16, also involved in mammalian select-
ive autophagy (Slobodkin & Elazar, 2013), could also par-
ticipate in P450 ALD. The identity of each of these
specific P450 ALD participants is currently unknown. In
addition to PI3K-inhibitors listed above, other diagnostic
ALD inhibitors include (i) bafilomycin A (BFA) that inhib-
its autophagosomal fusion and thus its maturation into
the autolysosome; (ii) NH4Cl or chloroquine that alkalin-
izes the acidic intralysosomal pH required for
proteolysis; and/or (iii) lysosomal protease inhibitors leu-
peptin, pepstatin, or E-64 (Mizushima et al., 2010).
Collective experimental evidence including the use of 3-
MA/NH4Cl as diagnostic probes has revealed that certain
P450s are largely degraded via ERAD/ALD, whereas only
a few others are normally so degraded (Correia, 2003;
Correia & Liao, 2007; Faouzi et al., 2007; Liao et al., 2005;
Masaki et al., 1987; Murray et al., 2002; Ronis &
Ingelman-Sundberg, 1989; Ronis et al., 1991; Roberts,
1997; Wang et al., 2011; Figure 3; see below).
Molecular/cellular determinants of P450 ERAD/UPD
versus ERAD/ALD selectivity?
Studies with diagnostic UPD/ALD inhibitors in cultured
human, mouse and rat hepatocytes (Figure 4) coupled
with those in S. cerevisiae strains with specific defects/
deletions of crucial UPD/ALD components, indicate that
CYPs 3A, either native or inactivated, largely incur UPD
(Correia et al. 1987, 1992a, 1992b, 2005; Correia, 2003;
Correia & Liao, 2007; Faouzi et al., 2007; Korsmeyer et al.,
1999; Liao et al., 2006; Murray & Correia, 2001; Roberts,
1997; Schmiedlin-Ren, 1997; Wang et al., 1999), whereas
native CYPs 2B1 and 2C11 largely incur ALD (Correia,
2003; Correia & Liao, 2007; Liao et al., 2005; Masaki et al.,
1987; Murray et al., 2002; Ronis & Ingelman-Sundberg,
1989; Ronis et al., 1991; Roberts, 1997; Wang et al.,
2011), and CYP2E1 incurs both processes (Dai &
Cederbaum, 1995; Morishima et al., 2005; Roberts, 1997;
Ronis & Ingelman-Sundberg, 1989; Ronis et al., 1991;
Sohn et al., 1991; Tierney et al., 1992; Wang et al., 2011).
Indeed, rat liver CYP2E1 and its mammalian orthologs
have been the first P450 proteins shown to incur
biphasic turnover with a rapid (t1/2, 7 h) and slow (t1/2,
37 h) phase that reflect its degradation via ERAD/UPD
and ERAD/ALD, respectively (Correia, 2003, and referen-
ces therein; Roberts et al., 1995; Song et al., 1989). The
rapid phase apparently stems from structural damage
inflicted by ROS generated by its futile oxidative cycling
in the absence or on withdrawal of an appropriate sub-
strate (i.e. EtOH or acetone), or even with a poorly
accepted substrate that permits ROS leakage from the
active site. By contrast, substrate binding at its active
site stabilizes the CYP2E1 protein conformation and pro-
longs its half-life (Correia, 2003; Roberts et al., 1995;
Song et al., 1989, and references therein), diverting it into
the slower ERAD/ALD pathway.
These collective observations along with the wide
range of P450 protein half-lives (Correia, 2003; and refer-
ences therein) imply that in spite of their equivalent ER-
co-residency, some degree of selectivity normally exists
in P450 sorting for degradation. What determines such
differential P450 molecular sorting into the ERAD/UPD
Figure 3. Autophagy in mammalian cells. The major steps in
ALD of cellular proteins and organelles are illustrated. ALD-
inhibitors that block the various steps and serve as diagnostic
probes are also shown. See discussion for details.
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and ERAD/ALD pathways? Plausible determinants
include: (i) Proclivity to futile oxidative cycling, and thus
a propensity for structural lesions in the catalytic
domain by engendered ROS that target the P450 pro-
tein to UPD, with a consequently shortened half-life.
Accordingly, genetic deletion of cytochrome P450
reductase (CPR), the sine qua non P450 redox partner,
and consequent abolition of P450 oxidative function
indeed results in the elevation of P450 hepatic content,
most likely via protein stabilization (Gu et al., 2003;
Henderson et al., 2003). This is also true when CPR func-
tion is chemically inhibited in cell culture (Goasduff &
Cederbaum, 1999; Zhukov & Ingelman-Sundberg, 1999).
Furthermore, just substrate (EtOH or acetone)-binding
to the CYP2E1 active site and catalysis, aborts its futile
cycling to ROS, thereby prolonging CYP2E1 half-life and
stabilizing the protein (Bardag-Gorce et al., 2006;
Chien et al., 1997; Roberts et al., 1995; Song et al., 1989).
Additionally, quasi-irreversible P450 inactivators such as
TAO that coordinate tightly to the CYP3A-ferrous heme
and abort its catalytic turnover, also dramatically pro-
long CYP3A half-life, resulting in the elevation of hepatic
CYP3A content (Watkins et al., 1986), another valid
example of P450 induction via protein stabilization.
However, in spite of this compelling evidence favoring
oxidative turnover as an ERAD/UPD determinant, argu-
ments for additional requirements exist. For instance,
heterologous expression of human CYP3A4 and CYP2E1
in S. cerevisiae whose basal CPR content is minimal, does
not deter their UPD or switch it completely to ALD, as
expected from their greatly diminished oxidative func-
tion (Liao et al., 2006; Murray & Correia, 2001; Wang
et al., 2011). This argues for the existence of additional
intrinsic structural features, barcodes or ‘‘degrons’’
Figure 4. 35S-pulse-chase analyses of CYP3A and CYP2B time-course in cultured rat hepatocytes. Cells were pulsed upon pretreat-
ment for 4 days with either phenobarbital, 1mM (A) or dexamethasone, 10 lM (B), following which they were pulse-chased with
35S-methionine/cysteine for 1 h in a methionine-cysteine-free WEM culture medium as described previously (Kim et al., 2010). The
culture medium was then exchanged with a medium containing cold methionine/cysteine, and harvested at 0, 1, 3 and 6 h there-
after. In parallel, similarly 35S-pulse-chased cultures were treated at time 0 h with either MG132 (10 lM) or 3-MA (5mM)/NH4Cl
(50mM). Cell lysates were immunopreciptated with either anti-CYP2B1 (A) or anti-CYP3A23 (B) antibodies. Aliquots of immunopreci-
pitates were subjected to SDS-PAGE and fluorography with Typhoon imaging (left panels). Smaller aliquots (10 lL) were subjected
to liquid scintillation counting (right panels). CT: control. Arrows depict the parent 50 kDa 35S-labeled P450 species.
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and/or posttranslational modifications to be involved in
P450 recognition, which determine whether any given
P450 is targeted to UPD or ALD. Accordingly, the
observed switch of heterologously expressed rat liver
CYP2B1 in S. cerevisiae from documented ERAD/ALD to
ERAD/UPD upon appendage of a CYP3A4 C-terminal
heptapeptide (Liao et al., 2005), reveals that a structur-
ally-flexible C-terminal tail was all that was required for
CYP2B1 to engage the 26S proteasome. Thus, it is con-
ceivable that some structural P450 modifications
acquired post-translationally (i.e. phosphorylation, ubiq-
uitination, acetylation?) or intrinsic structural features
unraveled by protein unfolding (i.e. concealed degrons
or LIRs; see below) may dictate this P450 sorting process.
Details of the nature of certain P450 structural determi-
nants such as surface linear and/or conformational
phosphodegrons and/or Lys48-linked polyubiquitination
that target proteins largely, if not exclusively to ERAD/
UPD are now emerging (Wang et al., 2011, 2012 and
2015).
UPD-recognition via linear and/or conformational
phosphodegrons
Degrons are usually specific short linear amino acid
sequences (often containing phosphorylatable S/T-resi-
dues that engender phosphodegrons), structural motifs
(unstructured/floppy C- and/or N-termini, disordered
loops) and/or cytosol-exposed amino acids (K, R) that
serve as hooks to engage different components of the
cellular degradation machinery thereby leading to the
molecular recognition and accelerated degradation of a
given protein. Such phosphodegrons appear to play a
key role in CYP3A4 E2/E3-recognition. Accordingly,
CYP3A4-ubiquitination in an in vitro functionally recon-
stituted UBC7/gp78- or CHIP-system, followed by tryp-
tic/lysyl endopeptidase C (Lys-C) digestion of the
ubiquitinated protein, and subsequent LC-MS/MS analy-
ses of the protein digest to monitor Ub-derived GG- or
LRGG-remnant modified CYP3A4 peptides, led to the
identification of various CYP3A4 ubiquitinated Lys (K)-
residues (Wang et al., 2012, 2015). Scrutiny of the avail-
able CYP3A4 crystal structures (Ekroos & Sjogren, 2006;
Sevriouka & Poulos, 2012; Williams et al., 2003; Yano
et al., 2004) reveal that these ubiquitinated K-residues,
along with previously identified PKA- or PKC-phosphory-
lated Ser and Thr (pS/pT)-residues reside within or are
vicinal to surface clusters of acidic [Asp (D), Glu (E)] resi-
dues (Figure 5). Based on this observation and various
other converging lines of literature evidence (discussed
in Wang et al., 2015) on the nature of other observed
P450 electrostatic protein–protein interactions (Bridges
et al., 1998; Gao et al., 2006; Lin et al., 2012; Zhao et al.,
2012), distinguishing structural features of E2-enzyme-
substrate interactions (Catic et al., 2004; Miao et al.,
2010), as well as the high propensity of observed D/E/S/
T-residues flanking ubiquitination sites within linear
peptides identified through global Ub-remnant profiling
analyses of the vast cellular ‘‘ubiquitinome’’ (Peng et al.,
2003; Kim et al., 2011; Udeshi et al., 2012, 2013; Wagner
et al., 2012; Xu et al., 2010), we proposed that such
negatively charged surface DEST-clusters through elec-
trostatic interactions with positively charged residues of
these E2/E3 systems would be critical to CYP3A4
molecular recognition (Correia et al., 2014; Wang et al.,
2012, 2015). Indeed, structural analyses of CYP3A4
K-ubiquitination verified that it not only occurs on con-
tiguous linear motifs (i.e. K282-E283-pT284-E285) along
disordered cytosol-exposed surface loops that conform
to canonical phosphodegrons, but also involves interac-
tions with D/E surface clusters spatially associated
with phosphorylatable S/T residues (i.e. E258-pS259-
E262-D263-pT264; K115-pS116-E122-D123-E124-E125)
that are assembled together by the P450 tertiary struc-
ture and thus represent ‘‘conformational’’ phosphode-
grons (Figure 5). Such P450 S/T phosphorylation by
imparting additional negative charge would further
boost the overall negative charge of a specific DEST
cluster (Correia et al., 2014; Wang et al., 2012, 2015),
thus serving as the molecular switch to enhance P450
recognition by an E2/E3-complex, thereby accelerating
P450 proteasomal degradation, and controlling the tim-
ing of its ERAD. Such a role of CYP3A4 phosphodegrons
in its recognition by gp78- and CHIP-ubiquitination
complexes was validated though several complemen-
tary approaches: Thus, (i) as expected, high salt treat-
ment was found to disrupt CYP3A4 electrostatic
interactions with subcomponents of each E2/E3-
complex thereby attenuating their CYP3A4 ubiquitina-
tion (Wang et al., 2015). (ii) Chemical-crosslinking of the
surface K-residues coupled with LC-MS/MS analyses
identified the specific intermolecular interaction-sites.
Thus, CYP3A4-K-residues cross-linked to these E2/E3-
components were found either flanking or vicinal to its
negatively charged surface clusters (identified above),
while the gp78-K-residues cross-linked to CYP3A4-K-resi-
dues resided within positively charged ‘‘basic patches’’
(Wang et al., 2015). (iii) Site-directed mutagenesis of the
positively charged residues within these gp78 basic
patches greatly attenuated gp78-mediated CYP3A4-
ubiquitination, thereby verifying the involvement of the
requisite electrostatic interactions (Wang et al., 2015).
(iv) Site-directed mutagenesis to Ala of D/E/S/T-residues
individually or in combination within relevant
negatively charged CYP3A4 surface-clusters was also
found to attenuate gp78- and/or CHIP-mediated
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CYP3A4-ubiquitination (Wang et al., 2015). Accordingly,
these analyses identified the E283-pT284-E285 cluster as
specifically relevant to CYP3A4 interaction with gp78,
and its E258-pS259-E262-D263-pT264 cluster to that
with CHIP (Wang et al., 2015).
Although, CYP2E1 interactions with these E2/E3
ligases have not been quite as extensively scrutinized,
our initial inspection of the CYP2E1 structure (Porubsky
et al., 2008) revealed that the previously identified
CYP2E1 PKA/PKC-phosphorylation (pS/pT) sites and its
UBC7/gp78 and CHIP-ubiquitination K-sites also reside
within or vicinal to negatively charged DEST surface
clusters (Figure 5; Correia et al., 2014; Wang et al., 2011).
Furthermore, the positively charged gp78-patches
required for CYP3A4-ubiquitination are similarly relevant
to its CYP2E1-ubiquitination (Figure 2). Preliminary find-
ings indicate that human liver CYPs 2C9, 2C19 and 2D6
are also targeted to gp78- and/or CHIP-mediated ubiqui-
tination in in vitro reconstituted systems (YQ Wang &
M. A. Correia, preliminary findings). Structural mapping of
each of these P450s (Reynald et al., 2012; Rowland et al.,
2006; Wang et al., 2012; Wester et al., 2004) reveals that
many of the surface K-residues lie either within or vicinal
to negatively charged DEST-clusters, thereby suggesting
this to be a common feature of these other gp78/CHIP-
ubiquitinatable P450s (Figure 6).
Lys48-linked polyUb chains
Ub contains seven internal K-residues (K6, K11, K27, K29,
K33, K48 and K63), and proteomic analyses reveal that
any of these residues can be utilized to form polymeric
Ub-chains that apparently are physiologically relevant
(Kulathu & Komander, 2012). The most common of
these Ub-chains is Lys48-linked polyubiquitination
(wherein the isopeptide linkage occurs between Lys48 of
the first Ub within the chain and/or conjugated to the
protein substrate and terminal Gly76 of the next Ub-mol-
ecule), which is generally believed to target proteins to
the 26S proteasome by tethering to the polyUb-recep-
tors (Rpn10/Rpn13 subunits) of the 19S proteasomal cap
(Finley, 2009; Pickart & Cohen, 2004; Rechsteiner, 2005).
The ideal Ub-chain length for such proteasomal target-
ing is 4–20 (Finley, 2009; Pickart & Fushman, 2004;
Pickart & Cohen, 2004; Rechsteiner, 2005), although
even shorter chains may suffice (Lu et al., 2015).
Figure 5. CYP2E1 and CYP3A4 structures with linear and ‘‘conformational’’ phosphodegrons: Previously identified phosphorylated
S/T-residues (green) and ubiquitinated K-residues are shown. The K-residues ubiquitinated by gp78-complex are colored red, those
ubiquitinated by CHIP-complex in blue, and those ubiquitinated by both E3-complexes in magenta. Note that these residues lie
within or in the vicinity of linear loops or clusters of pS/pT (green), D and E residues colored cyan and orange, respectively.
DRUG METABOLISM REVIEWS 415
These are directly elaborated on each available Lys-
eNH2 (or sometimes an N-terminal-aNH2) group of the
protein substrate, with larger/longer Ub-conjugates
being preferred and degraded at a faster rate
(Rechsteiner, 2005). Non-canonical Ub-linkages with sub-
strate cysteine, serine, and threonine residues also
occur, but these linkages are unstable and seldom sur-
vive the LC-MS/MS conditions required for their detec-
tion and interrogation of their physiological relevance
(Cadwell & Coscoy, 2005; Ishikura et al., 2010; Vosper
et al., 2009; Wang et al., 2007). In the case of CYP3A4
and CYP2E1, such Lys48-linked Ub-chains are found on
K-residues in surface loops and/or disordered regions,
within or vicinal to DEST-clusters, elaborated exclusively
by UBC7/gp78 E2/E3-complexes, but also to a respect-
able extent by the CHIP-system (Wang et al., 2011, 2012,
2015). Similarly, Lys29-chains conjugated directly to a
protein substrate are found to target to its proteasomal
destruction (Rechsteiner, 2005). On the other hand,
atypical Lys27-linked chains target misfolded proteins to
the 26S proteasome via Hsp70-Bag1 chaperone com-
plex, wherein Bag1 rather than the substrate is the tar-
get of such decoration (Rechsteiner, 2005). By contrast,
Lys6-linked Ub-chains are involved in DNA repair,
whereas Lys63-linked chains are involved in DNA repair,
endocytosis and ALD (see below).
P450 ERAD/ALD-recognition
By contrast to ERAD/UPD, the nature/identity of the
P450 ALD-determinants remains relatively obscure and
thus a promising area for future investigation.
Autophagic targeting generally involves at the least 3
interdependent mechanisms that we propose are rele-
vant to P450 ALD (Figure 7): (i) LIRs or LRS, LC3-interact-
ing regions as adapters (Birgisdottir et al., 2013;
Johansen & Lamark, 2011; Lamark et al., 2009; Stolz
et al., 2014); (ii) Monoubiquitination or Lys63-linked
polyubiquitination (Kim et al., 2008; Kirkin et al., 2009;
Linares et al., 2013; Mukhopadhyay & Riezman, 2007;
Seibenhener et al., 2004); and (iii) cargo receptors/adapt-
ers such as p62/sequestosome-1 (SQSTM1) and/or
NBR1 (neighbor of BRCA1 gene1) that bear the essential
LIR motif and serve to target mono- or Lys63-ubiquiti-
nated substrates to selective autophagy (Kim et al.,
2008; Kirkin et al., 2009; Linares et al., 2013;
Mukhopadhyay & Riezman, 2007; Olzmann et al., 2007;
Pankiv et al., 2007; Seibenhener et al., 2004).
Figure 6. Plausible linear and ‘‘conformational’’ phosphodegrons of other major human liver P450s: Surface DEST clusters are
shown with vicinal K-residues shown in yellow, S/T phosphorylation sites in green, D and E residues in cyan and orange, respect-
ively. Note that although neither the ubiquitination nor the phosphorylation sites have yet to be conclusively identified, their situ-
ation within or vicinal to DEST clusters is highly intriguing.
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LIRs
The central feature of this structural protein barcode
is a relatively conserved 8-amino acid linear sequence
(X-3X-2X-1W0X1X2LX3), required to dock at the hydropho-
bic Ub-like domain of LC3 and thus to target the
substrate to the nascent phagophore (Birgisdottir et al.,
2013; Ichimura et al., 2008; Johansen & Lamark, 2011;
Lamark et al., 2009; Noda et al., 2008; Stolz et al., 2014).
In this consensus motif, the W0-site absolutely has to be
an aromatic residue (W, F or Y), while the L-site includes
a large hydrophobic residue i.e. L, I, or V (Johansen &
Lamark, 2011). X-3X-2X-1 and X1 or X2 could be, but not
strictly, acidic D/E and/or phosphorylatable S/T residues.
Thus, the full consensus LIR motif may be written as D/
E/X-D/E/X-D/E/X-W/F/Y-D/E/X-D/E/X-L/I/V, and is fre-
quently abbreviated to the essential core W/F/YXXL/I/V
sequence (Birgisdottir et al., 2013; Ichimura et al., 2008;
Noda et al., 2008). It is also conceivable that some
globular structures such as the P450s may contain ‘‘con-
formational’’ LIRs, wherein the W0/XXL/I/V motif is
assembled together by the protein’s tertiary fold.
Inspection of various primary CYP2B amino acid
sequences reveals several relatively conserved linear LIR
motifs. However, the CYP2B4 crystal structure (i.e. appar-
ently conserved in CYP2B6 and possibly other CYPs 2B;
Halpert, 2011; Scott et al., 2003, 2004; Shah et al.,
2011) reveals that some LIRs are surface exposed
(REKY62GDV66F, FQGY111GVI114FAN GERW121RAL,
KDPVF195LRLL199, RQIY235RNL238QE, Y309GFLLMLKY317
PHV320T), while others are buried and would become
available only upon protein unfolding (Figure 8). This is
also true of CYP2E1 (Porubsky et al., 2008) and CYP2D6
(Wang et al., 2012), two human P450s targeted bimo-
dally to both ERAD/UPD and ERAD/ALD (Figure 9; see
below). Inspection of the CYP3A4 sequence reveals that
it too contains several LIR motifs. However, structural
comparison reveals a key difference in that the critical
aromatic W0-residue of most CYP3A4 LIRs unlike those
of CYP2B4- or CYP2E1-LIRs are concealed within the pro-
tein fold (Porubsky et al., 2008; Scott et al., 2003, 2004;
Williams et al., 2003; Yano et al., 2004; Figure 9), and
thus may not be readily accessible to the autophagic
machinery, unless the protein is unfolded. It is note-
worthy that LIR motifs are required but may not be suffi-
cient for autophagic targeting.
Monoubiquitination/Lys63-linked polyubiquitination
Increasing evidence indicates that ALD-substrates are
tagged via mono- or polyubiquitination [wherein the
isopeptide linkage is between Lys63 of the first Ub
attached to the target (or within the chain) and Gly76 of
the next Ub] (Kim et al., 2008; Kirkin et al., 2009; Linares
et al., 2013; Mukhopadhyay & Riezman, 2007;
Seibenhener et al., 2004). Such K63-linked polyubiquiti-
nation is involved in their p62-/NBR-1-recruitment and
subsequent targeting to ALD (Birgisdottir et al., 2013;
Johansen & Lamark, 2011; Lamark et al., 2009; Lamark
et al., 2009; Linares et al., 2013; Seibenhener et al., 2004;
Stolz et al., 2014). Our findings (Wang et al., 2011, 2012)
that CYPs 3A4 and 2E1 are not only ubiquitinated
in vitro by the UbcH5a/CHIP/Hsp70 E2-E3 complex with
almost equivalent K48- and K63-linkages, but also several
Figure 7. Plausible mechanisms of P450 autophagic targeting: Roles of hepatic p97/Npl4/Ufd1 complexes in ER-extraction, p62 and
NBR1 heteromers in autophagic targeting of ubiquitinated P450s via their LIR- and UBA-domains to the phagophore, and of p97/
p47 complexes in subsequent autophagosome biogenesis through fusion of the phagophore ends.
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human liver P450s incur both types of such linkages in
HepG2 cells upon transfection (Figure 10), suggest that
in the absence of functionally accessible LIRs, K63-linked
polyubiquitination may serve to target these proteins to
ALD via p62 and/or NBR1 cargo receptors (Figure 7).
p62 and/or NBR1 autophagic cargo receptors
Several (>24) autophagic cargo receptors such as p62/
sequestosome-1, NBR1, Bnip3 (Bcl-2/adenovirus E1B
19 kDa interacting protein 3) and NDP52 (nuclear dot
protein 52 kDa) have been identified in mammals (Bento
et al., 2016; Birgisdottir et al., 2013; Ichimura et al., 2008;
Johansen & Lamark, 2011; Katsuragi et al., 2015; Lamark
et al., 2009; Noda et al., 2008; Pankiv et al., 2007; Stolz
et al., 2014; von Muhlinen et al., 2010). Their function is
usually complementary, but redundant in some instan-
ces (Bento et al., 2016; Birgisdottir et al., 2013; Stolz
et al., 2014). To qualify as autophagic receptors these
proteins must recruit the phagophore to the cargo, lead-
ing to its selective autophagosomal engulfment. p62/
SQSTM1 and NBR1 are two structurally related mamma-
lian proteins that serve as cargo receptors for selective
autophagy of ubiquitinated substrates and/or ubiquiti-
nated aggregates (aggrephagy) (Bento et al., 2016;
Birgisdottir et al., 2013; Johansen & Lamark, 2011;
Lamark et al., 2009; Pankiv et al., 2007; Stolz et al., 2014).
Their relevant structural features include (i) a LIR motif
for docking with LC3 of the phagophore; (ii) a C-terminal
Ub-associated domain (UBA) for binding ubiquitinated
substrates; and (iii) a N-terminal PB-1 domain for oligo-
merization (Bento et al., 2016; Birgisdottir et al., 2013;
Johansen & Lamark, 2011; Lamark et al., 2009; Pankiv
et al., 2007; Stolz et al., 2014). They function coopera-
tively as heteromeric complexes of p62 polymers and
NBR1 oligomers that corral ubiquitinated substrates via
their UBA domain and ferry them to the nascent phago-
phore, guided by their LC3-docking LIR motif. However,
in some instances, the p62 LIR domain is dispensable
and just oligomerization of its PB-1 domain apparently
suffices (Itakura & Mizushima, 2011). Such oligomeriza-
tion is thought to enable sequestration and clustering of
the selected cargo. They are both selective autophagic
substrates, and their levels are regulated by ALD rather
than UPD (Bento et al., 2016; Birgisdottir et al., 2013;
Johansen & Lamark, 2011; Komatsu et al., 2007; Lamark
et al., 2009; Olzmann et al., 2007; Pankiv et al., 2007;
Stolz et al., 2014). Both p62 and NBR1 mediate protein
aggregation and are found in various pathologic inclu-
sions i.e. Mallory Bodies of alcoholic/nonalcoholic stea-
tohepatitis, and aggregates of neurodegenerative
Alzheimer’s, Huntington’s and Parkinson’s diseases
(Bjorkoy et al., 2005; Denk et al., 2006; Johansen &
Lamark, 2011; Komatsu et al., 2007; Strnad et al., 2008).
Figure 8. CYP2B4 versus CYP2B6 surface LIR-motifs. Two different orientations of CYP2B4, and CYP2B6 are shown based on their
individual structures (See discussion). The critical W0 aromatic residue of the essential LIR W/F/YXXL/I/V core motif is depicted as fol-
lows: Trp (blue), Phe (green), and Tyr (magenta), and the other LIR residues in yellow. The extended LIR motif (D/E/X-D/E/X-D/E/X-
W/F/Y-D/E/X-D/E/X-L/I/V) is also depicted in yellow, when present in the P450 primary sequence.
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Figure 9. Surface LIR-motifs of other human P450s. Two different orientations of CYP2C9, CYP2D6, CYP2E1 and CYP3A4 are shown
based on their individual structures (See discussion). The critical W0 aromatic residue and the other LIR residues of the essential LIR
W/F/YXXL/I/V core motif are depicted as follows: Trp (blue), Phe (green), and Tyr (magenta), and the other LIR residues in yellow.
The extended LIR motif (D/E/X-D/E/X-D/E/X-W/F/Y-D/E/X-D/E/X-L/I/V) is also depicted in yellow, when present in the P450 primary
sequence. Note that these critical W0-residues are largely buried in CYP3A4.
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Their relatively high abundance in the liver (Komatsu
et al., 2007), and their proclivity to target Lys63-ubiquiti-
nated substrates makes them potential candidates in
the selective autophagy of P450 proteins, particularly
those not so highly endowed with LIRs.
A role for p97 in P450 ALD?
p97, also known albeit incorrectly as VCP (Valosin-
Containing Protein), or Cdc48p in yeast, is at the cross-
roads of various cellular pathways (Anderson et al.,
2015; Bug & Meyer, 2012; Deshaies, 2014; Meyer et al.,
2012). It functions as discussed above in UPD, as a het-
erotrimeric complex with two additional heterodimeric
adapters, Ufd1 and Npl4, that assist in the recruitment
of polyubiquitinated target substrates to the p97-com-
plex (Bar-Nun, 2005; Chou et al., 2011; Dai & Li, 2001;
Elkabetz et al., 2004; Ikeda et al., 2009; Jentsch & Rumpf,
2007; Meyer et al., 2000; Richly et al., 2005; Xia et al.,
2016; Ye et al., 2005). In S. cerevisiae, this heterotrimeric
p97-complex is required for CYP3A ERAD/UPD (Liao
et al., 2006), a finding verified through crosslinking anal-
yses (Faouzi et al., 2007) and p97-targeted RNAi in cul-
tured rat hepatocytes. Besides UPD, p97 functions in
diverse cellular processes including homotypic mem-
brane fusion, vesicular transport, and non-UPD-medi-
ated degradation of cytosolic proteins (Chou et al., 2011;
Dreveny et al., 2004; Wojcik et al., 2006; Woodman,
2003; Xia et al., 2016). Highly intriguing reports suggest
a role for p97 in ALD (Chou et al., 2011). Accordingly, in
yeast, Cdc48, (the p97 homolog) together with its other
adapter p47 has been shown to function in autophago-
some biogenesis (Krick et al., 2010) and/or maturation
(Tresse et al., 2010). The dual role of p97 in ERAD/UPD
and ERAD/ALD reveals that it is strategically positioned
to regulate the relative P450 flux through each of these
degradation pathways (Chou et al., 2011; Ju et al., 2009;
Tresse et al., 2010). Whether it plays each role through
recruitment of different adapters (Ufd1/Npl4 in ERAD/
UPD vs p47 in ERAD/ALD) remains to be determined.
Equally plausible is that p97 could function concurrently
as a complex with its UPD adapters Ufd1/Npl4 to extract
ubiquitinated P450s from the ER and make them avail-
able to p62/NBR-1 or the phagophore, and/or as a com-
plex with its p47 ALD adapter in autophagosome
biogenesis/maturation (Figure 7), specific issues that
remain to be elucidated.
Relative UPD versus ALD-targeting of select
human liver P450s and their rat or mouse
orthologs: an update
In common with most aberrant/misfolded/damaged cel-
lular proteins, most mammalian P450s that are suicidally
and/or structurally damaged incur ERAD/UPD, (Correia
et al. 1987, 1992a, 1992b, 2005; Correia, 2003; Correia &
Liao, 2007; Dai & Cederbaum, 1995; Faouzi et al., 2007;
Korsmeyer et al., 1999; Liao et al., 2006; Lee et al., 2008;
Murray & Correia, 2001; Morishima et al., 2005; Roberts,
1997; Schmiedlin-Ren, 1997; Sohn et al., 1991; Tierney
et al., 1992; Wang et al., 1999). However, native P450s
not only are tagged with K48- and K63-linked Ub-chains,
Figure 10. K48- versus K63-linked P450 ubiquitination in HepG2 cells: Cells were transfected for 48 h with a C-terminally tagged
Myc/His6 P450 plasmid. The vector-containing medium was removed, cells washed, and then fresh medium added with MG-132, or
3MA/NH4Cl or no inhibitor (Control, CT). Six hours later, cells were harvested and lysates immunoprecipitated with antibodies to
anti-Myc antibodies, and immunoblotted with specific anti-K48-Ub or anti-K63-Ub IgGs. Note that all these P450s undergo both types
of ubiquitination. However, K48-linked Ub-chains accumulate upon inhibition with the proteasomal inhibitor MG-132, whereas K63-
linked Ub-chains accumulate upon 3MA/NH4Cl-mediated ALD inhibition. This may indicate that the type of ubiquitination per se is
not a determinant of P450 UPD or ALD. Additional factors (structural degrons, barcodes or adapters) must be involved.
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but also turnover bimodally via both ERAD/UPD and
ERAD/ALD (Figure 11). Thus, although a clear preference
for one pathway over the other exists, the specific
physiological determinants of such preferences are less
well understood. The discussion that follows attempts to
begin to fill this void and gain some insight from our
current knowledge of the proteolytic turnover of a few
select native P450s that significantly impact clinical ther-
apeutics and drug-drug interactions:
CYP2B6 and its mammalian orthologs
Cycloheximide-pulse-chase analyses coupled with the
use of a diagnostic UPD (MG132) or ALD (3MA/NH4Cl)
probe in HepG2 cells transfected with a C-terminally
Myc-tagged human liver CYP2B6 expression vector have
revealed that CYP2B6 largely incurs UPD, as no appre-
ciable stabilization of the parent ( 50 kDa) species is
detected upon treatment with the ALD inhibitors (3MA/
Figure 11. Cycloheximide-chase analyses of P450 turnover with UPD- or ALD-diagnostic probes. HepG2 cells were cultured and
transfected with each P450 plasmid vector for 48 h as in Figure 10. After washing and medium exchange, cells were treated with
cycloheximide (100lM) with or without MG132 or 3MA/NH4Cl as in Figure 10, followed by harvesting of cells at various times, and
immunoblotting of lysates with an anti-Myc antibody. (A) Temporal plots of parent 50 kDa P450 species, following densitometric
quantification. (B) Overexposure of the same immunoblots to reveal HMM ubiquitinated Myc-tagged-species. Note that all these
P450s are stabilized by the UPD-inhibitor, MG132 to some extent. However, only CYP2D6 and CYP2E1 parent and HMM-species are
significantly stabilized by the ALD probe 3MA/NH4Cl. Even CYP2C9 ( 50 kDa species) shows some stabilization upon 3MA/NH4Cl-
treatment at 24 h. No stabilization of CYP2B6 is appreciably detected.
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NH4Cl) with time. Although CYP2B6 is ubiquitinated via
both K48- and K63-Ub-chains (Figure 10), no accumula-
tion of CYP2B6 ubiquitinated species was detected how-
ever upon treatment with 3MA/NH4Cl, even at longer
times (24 h) (Figure 11), when such an accumulation
would have been observed, if CYP2B6 were indeed to
be significantly degraded via ERAD/ALD in intact cells.
Co-transfection of Myc-tagged CYP2B6 with either HA-
tagged gp78 or HA-tagged CHIP in HepG2 cells for 48 h,
and subsequent monitoring over a 6 h-period, excluded
either of these two E3 Ub-ligases in CYP2B6 ERAD/UPD,
thereby revealing that it’s UPD was dependent on an as
yet unidentified E3 ligase (Figure 12). Consistent with its
preference for ERAD/UPD, inspection of the CYP2B6
crystal structure (Halpert, 2011; Shah et al., 2011) reveals
that it contains several K-residues within or vicinal to
surface DEST clusters (Figure 6). However, as expected
from its low propensity for ALD, its surface LIR motifs
are largely Phe- or Tyr-based (wherein the critical W0 of
the LIR motif is F or Y, the weaker W0-residue), and the
only Trp-bearing W121KVL-LIR is buried within the pro-
tein-fold, unlike those of CYP2B4 (and possibly CYP2B1)
(Figure 8). A notable caveat is that these CYP2B6 analy-
ses relied on a C-terminally His6/Myc-tagged CYP2B6,
and it is plausible that such a C-terminal appendage
may have enabled its ERAD/UPD rather than ERAD/ALD
engagement (as observed previously with CYP2B1
appended with a CYP3A4 C-terminal heptapeptide; Liao
et al., 2005), a possibility being currently examined.
By contrast to CYP2B6, CYP2B1, its closely related
rat liver ortholog, has long been shown to be
predominantly an ALD substrate (Liao et al., 2005;
Masaki et al., 1987; Ronis & Ingelman-Sundberg, 1989;
Ronis et al., 1991). This preferential ALD sorting appears
to hold upon its heterologous expression in S. cerevisiae
as well (Liao et al., 2005), but is lost upon extension of
the CYP2B1 C-terminus (Liao et al., 2005). Furthermore,
35S-pulse-chase analyses of PB-pretreated cultured rat
hepatocytes reveal that CYP2B1 is stabilized largely by
3MA/NH4Cl, but to an appreciable extent also by
MG132, thereby indicating that CYP2B1 turnover is
bimodal in cultured rat hepatocytes opting predomin-
antly for ERAD/ALD, but ERAD/UPD as well to a signifi-
cant extent (Figure 4). This ALD-preference however
switches to UPD upon CYP2B1 inactivation (Lee et al.,
2008; Korsmeyer et al., 1999). CYP2B4 is quite robustly
ubiquitinated in vitro in a functionally reconstituted
CHIP-system (Morishima et al., 2005), consistent with the
possibility that this E3 is capable of elaborating K63-
linked Ub-chains that could target the protein to ALD
(Birgisdottir et al., 2013; Johansen & Lamark, 2011;
Lamark et al., 2009; Linares et al., 2013; Seibenhener
et al., 2004; Stolz et al., 2014).
CYP2C9 and other CYP2C proteins
Cycloheximide-pulse-chase analyses coupled with the
use of a diagnostic UPD (MG132) or ALD (3MA/NH4Cl)
probe in HepG2 cells transfected with a C-terminally
Myc-tagged human liver CYP2C9 expression vector have
revealed that this P450 also apparently turns over bimo-
dally: A fraction of the parent 50 kDa incurs ERAD/UPD
Figure 12. Relative role of CHIP- or gp78-E3 ligases in human P450 degradation: Myc/His6-tagged P450 plasmids were cotransfected
with either HA-tagged CHIP or gp78 E3 ligases or their structural deletion constructs in HepG2 cells. As previously, CYP2E1 and
CYP3A4 degradation is known to require both E3 ligase complexes for maximal degradation, and served as controls. Degradation of
CYP2C9 similarly required both functionally relevant CHIP and gp78 E3-ligases, as the deletion of the CHIP catalytic U-box or Hsp70-
interacting domain or of the gp78-E2-interacting or Cue-domains aborted their degradation whereas CYP2D6 degradation required
CHIP, but not gp78-E3-ligase. CYP2B6 is ubiquitinated (Figure 10), but its degradation appears to be independent of either E3 ligase.
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early and thus is largely stabilized by MG132, and a frac-
tion that undergoes ERAD/ALD and is stabilized around
12–24 h by 3MA/NH4Cl (Figure 11A). Although Myc-pull-
down studies indicate that CYP2C9 undergoes both K48-
or K63-linked ubiquitination (Figure 10), no accumulation
of ubiquitinated CYP2C9 species is detected upon UPD
or ALD inhibition (Figure 11B), although stabilization of
the parent species is clearly detected (Figure 11A).
Furthermore, both CHIP and gp78 E3-complexes are
involved in its ubiquitination, which requires their func-
tionally active catalytic U-box and RING-domains,
respectively. Accordingly, the CYP2C9 protein is signifi-
cantly degraded upon co-transfection of either HA-
tagged E3 ligase into HepG2 cells (Figure 12). Whether
in common with CYP3A4 (Wang et al., 2015), this
CYP2C9 CHIP/gp78-mediated ubiquitination is hierarch-
ical and/or synergistic in character, remains to be deter-
mined. Consistent with this dual E3-involvement,
inspection of a CYP2C9 crystal structure (Wester et al.,
2004) reveals that it is studded with K-residues also situ-
ated within or vicinal to negatively charged surface
DEST-clusters (Figure 6). Such structural scrutiny also
reveals the presence of Trp-, Phe- and Tyr-based LIR
motifs (Figure 9), thereby possibly accounting for its
sorting to the ALD pathway as well. Preliminary findings
reveal that native CYP2C19 is also ubiquitinated by both
CHIP and gp78-E3-ligases. On the other hand, rat liver
CYP2C11 incurs ERAD/ALD upon heterologous expres-
sion in S. cerevisiae (Murray et al., 2002), but upon sui-
cide inactivation it is ubiquitinated and apparently
proteasomally degraded, as revealed by the stabilization
of the ubiquitinated CYP2C11 species by the proteaso-
mal inhibitor hemin (Correia et al., 2005). A SILAC-based,
Ub-remnant profiling/proteomic analyses of wild type
and CHIP-deficient (CHIP/) hepatocytes revealed that
mouse liver CYPs 2C67 and 2C70 are appreciably ubiqui-
tinated by CHIP, and CYPs 2C29, 2C50, 2C54, and 2C37
to a lesser extent (S-M Kim & M. A. Correia, unpublished
observations). Their relative sorting to ERAD/UPD vs
ERAD/ALD, if any, remains to be elucidated.
CYP2D6 and its orthologous CYP2D proteins
Parallel cycloheximide-pulse-chase analyses coupled
with the use of a diagnostic UPD (MG132) or ALD (3MA/
NH4Cl) probe in HepG2 cells transfected with a C-ter-
minally Myc-tagged human liver CYP2D6 expression
vector have revealed that this P450 also turns over,
albeit slowly, via both UPD and ALD with a fraction of
the parent 50 kDa that is largely stabilized by MG132,
and another fraction that is stabilized by 3MA/NH4Cl
(Figure 11A). CYP2D6 incurs both types of K48- and K63-
linked ubiquitination (Figure 10), and this was confirmed
upon treatment with either MG132 or 3MA/NH4Cl, as
both probes stabilized HMM ubiquitinated CYP2D6 spe-
cies to a significant extent (Figure 11B). Co-transfection
studies in HepG2 cells with HA-tagged E3-ligases
revealed that CYP2D6 is a CHIP-, but not a gp78-ubiqui-
tination substrate (Figure 12). Structural inspection of
CYP2D6 (Wang A et al., 2012) also reveals the presence
of K-residues associated with surface DEST clusters
(Figure 6), as well as surface LIR-motifs, hallmarks of a
suitable autophagic target (Figure 9).
Preliminary examination of its mouse CYP2D10 ortho-
log using a SILAC-based, Ub-remnant profiling/proteomic
approach in wild type and CHIP-deficient (CHIP/)
hepatocytes (S-M Kim & M. A. Correia, unpublished obser-
vations), revealed that genetic ablation of CHIP greatly
reduced CYP2D10 ubiquitination, thereby validating this
CYP2D ortholog as a CHIP target. Furthermore, prelimin-
ary studies in cultured hepatocytes from an autophagy-
deficient (ATG5/) mouse also revealed a significant sta-
bilization of CYP2D10 (DY Kwon, Y. Liu and M. A. Correia,
preliminary findings), thereby revealing that it is a plaus-
ible ALD-substrate.
CYP2E1 and orthologous proteins
The reportedly biphasic/bimodal turnover of human
liver CYP2E1 was confirmed through our cycloheximide-
pulse-chase analyses coupled with the use of a diagnos-
tic UPD (MG132) or ALD (3MA/NH4Cl) probe in HepG2
cells transfected with a C-terminally Myc-tagged human
liver CYP2E1 expression vector (Figure 11A), as well as in
in cultured human hepatocytes and S. cerevisiae follow-
ing heterologous expression (Wang et al., 2011). The sig-
nificant accumulation of CYP2E1 ubiquitinated species
upon inhibition of either UPD or ALD is consistent with
its biphasic/bimodal turnover (Figure 11B). In common
with CYP3A4, it is a substrate of both CHIP- and gp78-
E3-ligases, and this was confirmed in cell culture as well
as upon cotransfection with either HA-tagged E3-ligase
(Figure 12). Its recognition by these E3-ligases appar-
ently also involves electrostatic interactions through
negatively charged surface conformational phosphode-
grons, consistent with the findings that its ubiquitina-
tion by gp78 was considerably attenuated upon
site-directed mutation of positively charged gp78-
patches (Figure 2). Inspection of CYP2E1 structure
(Porubsky et al., 2008) reveals that its ubiquitinated
K-residues are spatially associated with negatively
charged surface DEST-clusters (Figure 5). However, it
also has highly cytosol-accessible LIR-motifs that are
Trp-, Phe- and Tyr-based (Figure 9).
Mouse CYP2E1 has been documented to turn over
upon CCl4-mediated inactivation via ERAD/UPD
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(Tierney et al., 1992), and recombinant rabbit CYP2E1 to
be a CHIP substrate (Morishima et al., 2005). Preliminary
studies employing a SILAC-based, Ub-remnant profiling/
proteomic approach in cultured wild type and CHIP-defi-
cient mouse hepatocytes, revealed that genetic ablation
of CHIP also greatly reduced CYP2E1 ubiquitination,
thereby validating this CYP2E1 ortholog as a bona fide
CHIP target.
CYP3A4 and orthologous CYP3A proteins
Previous 35S-methionine/cysteine pulse-chase analyses
of the CYP3A protein degradation in cultured rat hepa-
tocytes (Faouzi et al., 2007) or incubation of rat hepato-
cytes in suspension (Wang et al., 1999) have revealed
that rat liver CYPs 3A, either native or suicidally inacti-
vated, are predominantly turned over via UPD as evi-
dent by the stabilization of the parent ( 55 kDa) and
ubiquitinated species ( 65 to>250 kDa) species by the
proteasomal inhibitors MG132 or MG262 (Figure 4;
Faouzi et al., 2007; Wang et al., 1999). A small but
detectable stabilization of the parent protein ( 55 kDa)
is also observed from 3–6 h upon treatment with the
ALD inhibitors 3MA/NH4Cl (Figure 4), thereby suggesting
that ALD may also normally contribute to a small extent
to their physiological turnover. This preferential ERAD/
UPD sorting also holds upon heterologous expression of
CYP3A4 in S. cerevisiae (Liao et al., 2006; Murray &
Correia, 2001), and upon 35S-pulse-chase analyses in
HEK293T cells (Wang et al., 2009) or HepG2 cells (Wang
et al., 2012), transfected with a CYP3A4 expression vec-
tor, yielding half-lives (t1/2) of such transfected wild-type
CYPs 3A4 and 3A5 proteins of 13.2 h and 15.9 h, respect-
ively, in HepG2 cells (Wang et al., 2012). Consistent with
a role for post-translational CYP3A4 phosphorylation,
PKA or PKC inhibitors attenuated this CYP3A4 turnover
(Wang et al., 2012), as did the combined mutation of
phosphorylatable CYP3A4 S478, T264 and S420 residues
(Wang et al., 2012). As discussed above both CHIP and
gp78 E3 Ub-ligase complexes are involved in CYP3A4
targeting to ERAD/UPD, and their recognition of this
substrate entails linear as well as conformational phos-
phodegrons along cytosol-exposed surface loops and/or
disordered regions (Wang et al., 2015). Consistent with
its predominant ERAD/UPD targeting, CYP3A4’s LIR
motifs, although present, are not all that cytosol-access-
ible (Figure 9).
Pathophysiological relevance of P450
degradation
Throughout their cellular lifespan, from their birth as
nascent chains that fold into mature functional
hemoproteins integrated into the ER, their subsequent
oxidative insults stemming from their catalytic function
and/or accidental encounters with suicide inactivators,
to their age-defined senescence, cellular P450s are sub-
ject to proteolytic turnover via ERAD/UPD and/or ERAD/
ALD, as discussed above. ERAD/UPD not only disposes
structurally damaged/inactive P450s as cellular garbage
(Correia, 2003; and references therein), but also plays a
major role in the clinically relevant polymorphic expres-
sion of human liver P450s through clearance of various
defective, misfolded and/or proteolytically susceptible
P450 variants (Liao et al., 2010; and references therein).
Thus, the R186G mutant encoded by the naturally
occurring CYP2C8*8 allelic variant is unstable upon
expression in COS-1 cells, but this instability can be
greatly attenuated in the presence of MG-132 (Hichiya
et al., 2005). Such clearance of aberrant P450 variants is
vital both for quality control and to prevent proteotoxic
stress due to the intracellular accumulation of abnor-
mal/aberrant and/or structurally damaged proteins.
Furthermore, such accelerated clearance of polymorphic
P450 variants may also have a beneficial protective role.
For example, CYP1B1.4 (bearing a N453S mutation) is
poorly expressed relative to its CYP1B1 N453 variants
genetically associated with increased risk of endometrial
cancer. Upon expression in COS-1 cells and pulse-chase
analysis, CYP1B1.4 N453S mutant is indeed degraded
much faster than CYP1B1.1 N453 via ERAD/UPD
(Bandiera et al., 2005). Consistently, individuals carrying
this CYP1B1.4 N453S mutation apparently exhibit a
lower incidence of such cancers than those carrying the
CYP1B1.1 N453 variants (Bandiera et al., 2005).
More importantly, and quite not all that well appre-
ciated is the fact that ERAD/UPD significantly contrib-
utes to the regulation of basal hepatic microsomal
P450 content and thus its function, and is conse-
quently a therapeutically relevant determinant of clin-
ical hepatic drug metabolism and elimination and
associated pharmacokinetic/pharmacodynamic drug-
drug interactions (Chien et al., 1997; Kalgutkar et al.,
2007; Liao et al., 2010; Xu et al., 2009; Yang et al.,
2008). Accordingly, 35S-pulse-chase analyses of cul-
tured rat hepatocytes reveals that ERAD/UPD controls
the amount of the newly synthesized/folded protein
by limiting the fraction of nascent CYP3A4 chains that
is actually incorporated into the ER-membrane at any
given time, and thence folded into the mature func-
tional P450 protein (Faouzi et al., 2007; Wang et al.,
1999). Indeed, a significant fraction of these de novo
synthesized 35S-CYP3A chains are ubiquitinated imme-
diately upon 35S-pulse-chase and detected as HMM
35S-CYP3A species, targeted for proteasomal degrad-
ation (Faouzi et al., 2007; Wang et al., 1999).
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Another important feature of this P450 regulation by
ERAD/UPD is the observed marked increase in hepatic
ER-integral CYP3A content that is fully functional follow-
ing lentiviral shRNAi directed against either gp78 or
CHIP E3 Ub-ligase (Kim et al., 2010; see below). This
reveals that each of these E3s in addition to targeting
irreversibly damaged P450s, also targets either native
P450s or an intermediate species, and thus regulates
functional hepatic P450 content. These findings provide
compelling support for ERAD/UPD as an important
physiological regulator of hepatic P450 content and
function, and not just a mechanism for disposal of
fatally damaged and/or functionally dead P450s.
Consequently, any elevation of functional P450 content
through impairment or disruption of hepatic P450 ERAD
would not only be therapeutically relevant, but also
pathologically relevant given the propensity of some
P450s such as CYP2E1 largely, and CYP3A4 to a smaller
extent to generate pathogenic ROS.
Indeed, this high propensity for generating ROS has
implicated CYP2E1 in the pathogenesis of toxic liver
damage, alcoholic liver disease, NASH (nonalcoholic
steatohepatitis), diabetes, and obesity (Bardag-Gorce
et al., 2006; Cederbaum, 2006; Cederbaum et al., 2013;
Schattenberg & Czaja, 2005; 2014). Although CYP2E1
normally comprises only 5–7% of total human hepatic
P450 content, its abnormal elevation above this basal
content (>7%) in these conditions either via transcrip-
tional induction or protein stabilization is thought to
promote liver injury (Bardag-Gorce et al., 2006;
Cederbaum, 2006; Cederbaum et al., 2013; Guengerich,
2015; Schattenberg & Czaja, 2005, 2012). Thus, tight
regulation of basal CYP2E1 content through carefully
balanced control of its de novo synthesis as well as
ERAD is clinically desirable. Indeed, we find that disrup-
tion of CYP2E1 ERAD/UPD through genetic ablation of
CHIP in mice (CHIP-/-) is associated with hepatic CYP2E1
elevation and consequent oxidative liver damage, up-
regulated pathogenic JNK-signalling and microvesicular
steatosis (Kim et al., 2016b). On the other hand, ERAD/
ALD is equally important in CYP2E1 regulation as docu-
mented by the finding that its disruption via genetic
ablation or siRNA-elicited knockdown of specific ALD-
relevant genes (Atg7) in CYP2E1-expressing E47 HepG2
cells, stabilizes CYP2E1 thereby promoting acute chem-
ically induced CYP2E1-dependent cytoxicity (Wu &
Cederbaum, 2013). This acute cytoxicity is manifested
through increased ROS production, oxidative stress,
reduced E47 cell viability, and necrosis that were all fur-
ther magnified upon ALD disruption by 3-MA-elicited
autophagic inhibition (Wu & Cederbaum, 2013).
An additional pathophysiologic consideration is that
ERAD/UPD may also be responsible for generating
pathogenically relevant serum P450 autoantibodies in
individuals with chronic active and drug-induced hepa-
titis and hypersensitivity reactions (Beaune et al., 1987;
Bourdi et al., 1992, 1996; Boitier & Beaune, 2000;
Dansette et al., 1998; Eliasson & Kenna, 1996; Leeder
et al., 1996; Riley et al., 1993; Thervet et al., 2005;
Uetrecht, 1999, 2005), associated with the therapeutic
intake of CYP3A (carbamazepine and phenytoin),
CYP2E1 (halothane) and CYP2C9 (tienilic acid) sub-
strates. Thus, proinflammatory and/or oxidative stress
conditions that are known to induce the immunoprotea-
some ‘‘i-proteasome’’ (through exchange of the consti-
tutive catalytic b1-, b2- and b5–20S-proteasomal
subunits with the inducible LMP2, MECL1 and LMP7-
subunits of the i-proteasome; Ferrington & Gregerson,
2012; Kloetzel, 2004; Michalek et al., 1993; Monaco,
1995), may enable the generation of P450-peptides that
are covalently drug-modified and/or with a hydrophobic
C-terminus that can be recognized by the MHC class
I molecules for antigenic presentation at the cell surface.
The degradation of cellular proteins including hepatic
P450s and/or organelles via ERAD/UPD and/or ERAD/
ALD is a basal, physiologic housekeeping function.
Because these processes control a myriad of vital cellu-
lar functions, their dysfunction is intricately linked not
only to P450-linked therapeutic misadventures, but also
to many human diseases such as cancer, neurodegener-
ation (Alzheimer’s, Parkinson’s, and Huntington’s dis-
eases), myodegeneration, diabetes, Paget’s disease of
bone, cystic fibrosis, microbial infection, immunity and
ageing (Bjorkoy et al., 2005; Cuervo, 2011; Komatsu,
2012; Komatsu et al., 2012; Manley et al., 2013; Madrigal-
Matute & Cuervo, 2015; Mizushima et al., 2008; Nezis
et al., 2012; Puissant et al., 2012; Rabinowitz & White,
2010; Zhang et al., 2015; reviewed by Guerriero & Brodsky,
2012). Disruption of these inherently protective and
homeostatic mechanisms, can lead to apoptosis or cell
death.
Indeed, this very likelihood that disruption of these
physiologic ERAD processes can trigger ER stress and
consequent proteotoxic crisis and apoptosis has
prompted the exploitation of proteasomal inhibitors in
cancer therapy (Deshaies, 2014; Johnson, 2015). Unlike
their normal counterparts, cancer cells operate at
highly accelerated protein turnover rates, and inhib-
ition of their protein degradation could drive them
quite easily into an unfolded protein response/ER-
stress that triggers apoptosis. Both reversible proteaso-
mal inhibitors such as bortezomib, its orally active
analog MLN9708, and delanzomib, as well as irrevers-
ible inhibitors such as the epoxy-ketone inhibitor, car-
filzomib and its orally active analog oprozomib, and
the naturally occurring b-lactone marizomib
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(salinosporamide A) are either in use or actively con-
sidered in cancer chemotherapy (Deshaies, 2014;
Johnson, 2015). Although these compounds are effect-
ive against hematological/plasma cell malignancies
such as multiple myeloma and mantle cell lymphoma,
they are ineffective against solid tumors. One reason
is that proteasomal blockade causes proteins to accu-
mulate in the cytosol after their ER-extraction rather
than within the ER, thereby minimizing the levels of
ER-stress within the ER, and the required magnitude
of ‘‘proteotoxic crisis’’ (Deshaies, 2014). The other even
more important one is that because the proteasome is
an essential homeostatic protein, its inhibition leads to
its rebound synthesis (Deshaies, 2014), thus requiring
higher, potentially toxic, pharmacological dosages of
its inhibitors for an efficacious cancer therapeutic
response.
This realization has fostered the consideration and
pharmaceutical development of p97 inhibitors. As dis-
cussed earlier, p97 is not only at the crossroads of
several physiologic pathways, but it is actively
involved in extracting proteins from both the ER-
lumen and ER-membrane. Thus, blockade of its func-
tion would heighten the magnitude of the ER-stress,
and the consequent extent of the proteotoxic crisis
and apoptosis. Indeed, several p97 inhibitors have
been developed in recent years (reviewed in Deshaies,
2014). Of these, the most potent, selective and orally
bioavailable p97 inhibitor is CB-5083, a very promising
agent that not only disrupts UPD, but also activates
ER-stress and autophagic pathways in non-small-cell
lung cancer cells (Anderson et al., 2015). Given its
pharmacologic/pharmacokinetic profile and the docu-
mentation of its effectiveness in both hematological
as well as solid tumor animal models (Anderson et al.,
2015), this compound is currently in Phase I trials
both in patients with relapsed and refractory multiple
myeloma and in patients with advanced solid tumors
(Anderson et al., 2015). For the sake of completeness,
it must be stated that compounds that target E3 Ub-
ligases are also currently being considered as cancer
chemotherapeutic agents, in an attempt to block the
proteolytic turnover of their tumor suppressor sub-
strates and prolong their life spans (Deshaies, 2014).
Thus, although the disruption of the physiologic ERAD
function can be detrimental to normal cells, it can be
strategically exploited to mitigate various pathogenic/
pathologic conditions. In conclusion, the therapeutic
relevance of P450 turnover notwithstanding, given the
physiological and pathophysiological relevance of
these vital ERAD pathways, as their prototypic sub-
strates, the ER-integral P450s serve at a more
fundamental level, as excellent probes for their mech-
anistic dissection and characterization.
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